Results 1 to 10 of about 15,495 (164)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

Frontiers in Pharmacology, 2020
BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme ...
Ayman F Refaie, Hussein Sheashaa, George P Patrinos   +2 more
exaly   +3 more sources

Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico

Frontiers in Pharmacology, 2020
CYP3A5 metabolizes endogenous substrates and ~30% of prescription drugs. The CYP3A5 gene contains an active CYP3A5*1 allele, and a non-functional version, the CYP3A5*3 (rs776746), with consequences for drug therapeutic responses and side effects.
Carlos Galaviz-Hernandez, Hector Rangel-Villalobos   +1 more
exaly   +3 more sources

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. [PDF]

, 2012
To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection.
A Habtewold, A Kwara, A Patel, A Tostmann, A Tostmann, A Tostmann, A Turkova, AK Daly, AM Anderson, B Lopman, BS Kappelhoff, C Benichou, C Nyakutira, CJ Hoffmann, CJ Hoffmann, D Voora, DF Wares, E Aklillu, E Aklillu, E Lopez-Lopez, E Ngaimisi, E Ngaimisi, E Pukenyte, Eleni Aklillu, Eliford Ngaimisi, Eric Sandstrom, Ferdinand Mugusi, G Yimer, G Yimer, G Yimer, GJ Dore, GL Dean, JG Stine, JJ Saukkonen, JK Mukonzo, JR Ungo, Juergen Burhenne, K Cohen, Klaus-Dieter Riedel, Lars Lindquist, LK Shipton, M Fiegenbaum, M Nelson, MI Matee, Mohamed Janabi, Muhammad Bakari, N Abrescia, N Soleman, Omary Minzi, P Kuehl, P Ocama, Petros C. Karakousis, R Kalyesubula, R Singla, RA Mirghani, S Russmann, Sabina Mugusi, SC Figueroa, SF Mugusi, V Gounden, W Mankhatitham, Z Desta, ZS Lamar   +62 more
core   +11 more sources

Effects of genetic polymorphism of CYP3A4 and CYP3A5 on analgesic efficacy of postoperative intravenous analgesia with sufentanil in patients after laparoscopic surgery

Di-san junyi daxue xuebao, 2022
Objective To explore the differences of postoperative patient-controlled intravenous analgesia (PCIA) with sufentanil in the patients with different CYP3A4 and CYP3A5 genotypes after laparoscopic surgery. Methods According to CYP3A4 and CYP3A5 genotypes,
GU Li, ZHOU Li, LI Yongshuai, FENG Liyuan, CHEN Xingtong   +4 more
doaj   +1 more source

Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease

Scientific Reports, 2021
CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders.
Kevin A. Lidberg, Andrew J. Annalora, Marija Jozic, Daniel J. Elson, Lu Wang, Theo K. Bammler, Susanne Ramm, Maria Beatriz Monteiro, Jonathan Himmelfarb, Craig B. Marcus, Patrick L. Iversen, Edward J. Kelly   +11 more
doaj   +1 more source

Individualized treatment based on single-nucleotide polymorphisms with tacrolimus in ulcerative colitis [PDF]

Intestinal Research, 2019
Background/Aims The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending ...
Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, Osamu Takeuchi, Toshifumi Hibi   +11 more
doaj   +1 more source

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. [PDF]

PLoS ONE, 2016
To assess the impact of the loss-of-function CYP3A5*3 allele (rs776746, 6986A>G SNP) on darunavir (DRV) plasma concentrations.135 HIV-1 infected patients treated with DRV-based therapy were included in the study and plasma samples were obtained ...
Leïla Belkhir, Laure Elens, Francis Zech, Nadtha Panin, Anne Vincent, Jean Cyr Yombi, Bernard Vandercam, Vincent Haufroid   +7 more
doaj   +1 more source

Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients

Korean Journal of Transplantation, 2020
Background : Renal transplant is an effective treatment option for end-stage kidney disease and tacrolimus is one of the most commonly used immunosuppressant drugs in renal transplant patients.
Yi Yi Htun, Nwe Nwe Than, Htar Kyi Swe
doaj   +1 more source

Alleles of CYP3A5 and their association with renal function in chronic kidney disease [PDF]

PeerJ
Background The cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) gene plays an important role in renal function through its product’s involvement in metabolizing endogenous substances and drugs, including immunosuppressants used following ...
Onnapa Kongphan, Worachart Lert-itthiporn, Ubon Cha’on, Sirirat Anutrakulchai, Kanokwan Nahok, Nadthanicha Artkaew, Chanpen Sriphan, Apinya Jusakul   +7 more
doaj   +2 more sources

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients

Frontiers in Pharmacology, 2021
Purpose: The drug-drug interactions (DDIs) of tacrolimus greatly contributed to pharmacokinetic variability. Nifedipine, frequently prescribed for hypertension, is a competitive CYP3A5 inhibitor which can inhibit tacrolimus metabolism.
Yilei Yang, Xin Huang, Yinping Shi, Rui Yang, Haiyan Shi, Xinmei Yang, Guoxiang Hao, Yi Zheng, Jianning Wang, Lequn Su, Yan Li, Wei Zhao, Wei Zhao   +12 more
doaj   +1 more source